Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells $11,799.84 in Stock

Key Points

• Carole Ho, an insider at Denali Therapeutics, sold 806 shares for a total of $11,799.84 on August 13, reducing her position by 0.37% and retaining 216,585 shares valued at approximately $3.17 million.
• Denali Therapeutics reported a loss of $0.72 earnings per share in its latest quarterly results, slightly better than the consensus estimate of a loss of $0.74.
• Despite recent insider selling, Denali Therapeutics has seen positive ratings from analysts, with an average price target of $33.85 and a prevailing rating of "Buy."

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Carole Ho sold 806 shares of the stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $14.64, for a total value of $11,799.84. Following the sale, the insider directly owned 216,585 shares in the company, valued at approximately $3,170,804.40. The trade was a 0.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Carole Ho also recently made the following trade(s):

• On Tuesday, August 12th, Carole Ho sold 2,937 shares of Denali Therapeutics stock. The shares were sold at an average price of $13.58, for a total value of $39,884.46.

Denali Therapeutics Trading Down 2.4%

Shares of NASDAQ DNLI traded down $0.35 during midday trading on Thursday, reaching $14.46. 1,767,093 shares of the stock were exchanged, compared to its average volume of 1,717,922. The business has a 50-day simple moving average of $14.30 and a two-hundred day simple moving average of $15.42. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -5.16 and a beta of 1.36. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 9.56.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the business earned ($0.59) earnings per share. As a group, equities research analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on DNLI. Robert W. Baird decreased their price target on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. HC Wainwright decreased their price target on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Wedbush lowered their target price on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, TD Cowen raised Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Denali Therapeutics currently has an average rating of "Buy" and an average price target of $33.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its stake in Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after buying an additional 1,551 shares during the last quarter. Sterling Capital Management LLC grew its stake in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after buying an additional 1,516 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Denali Therapeutics during the 1st quarter worth approximately $41,000. GF Fund Management CO. LTD. acquired a new stake in shares of Denali Therapeutics in the fourth quarter valued at approximately $62,000. Finally, Point72 Hong Kong Ltd acquired a new stake in Denali Therapeutics during the fourth quarter worth approximately $65,000. Institutional investors and hedge funds own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.